


A Spontaneous Aggressive ER α + Mammary Tumor Model Is Driven by Kras Activation

Graphical Abstract



Authors

Katie M. Campbell, Kathleen A. O'Leary, Debra E. Rugowski, ..., Malachi Griffith, Linda A. Schuler, Obi L. Griffith

Correspondence

linda.schuler@wisc.edu (L.A.S.),
obigriffith@wustl.edu (O.L.G.)

In Brief

Campbell et al. identify highly recurrent *Kras*-activating mutations in spontaneous prolactin-induced ER α + mammary tumors in female mice. This mimics the association between elevated prolactin and risk of ER α + breast cancer in postmenopausal women, providing a useful model for an important subset of aggressive clinical ER α + breast cancers.

Highlights

- Genomic analyses are performed on prolactin-induced ER α + murine mammary tumors
- *Kras* is recurrently mutated in tumors, suggesting a selective bottleneck
- Tumors exhibit reduced STAT5A and low lymphocytic infiltrate
- Genomic profiling is required to assess translational effect of murine models



A Spontaneous Aggressive ER α + Mammary Tumor Model Is Driven by Kras Activation

Katie M. Campbell,¹ Kathleen A. O'Leary,² Debra E. Rugowski,² William A. Mulligan,² Erica K. Barnell,¹ Zachary L. Skidmore,¹ Kilannin Krysiak,^{1,3} Malachi Griffith,^{1,3,4,5} Linda A. Schuler,^{2,6,7,*} and Obi L. Griffith^{1,3,4,5,7,8,*}

¹McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO 63108, USA

²Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI 53706, USA

³Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63108, USA

⁴Department of Genetics, Washington University School of Medicine, St. Louis, MO 63108, USA

⁵Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63108, USA

⁶University of Wisconsin Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53706, USA

⁷Senior Author

⁸Lead Contact

*Correspondence: linda.schuler@wisc.edu (L.A.S.), obigriffith@wustl.edu (O.L.G.)

<https://doi.org/10.1016/j.celrep.2019.06.098>

SUMMARY

The NRL-PRL murine model, defined by mammary-selective transgenic rat prolactin ligand *rPrI* expression, establishes spontaneous ER+ mammary tumors in nulliparous females, mimicking the association between elevated prolactin (PRL) and risk for development of ER+ breast cancer in postmenopausal women. Whole-genome and exome sequencing in a discovery cohort (n = 5) of end-stage tumors revealed canonical activating mutations and copy number amplifications of *Kras*. The frequent mutations in this pathway were validated in an extension cohort, identifying activating *Ras* alterations in 79% of tumors (23 of 29). Transcriptome analyses over the course of oncogenesis revealed marked alterations associated with *Ras* activity in established tumors compared with preneoplastic tissues; in cell-intrinsic processes associated with mitosis, cell adhesion, and invasion; as well as in the surrounding tumor environment. These genomic analyses suggest that PRL induces a selective bottleneck for spontaneous *Ras*-driven tumors that may model a subset of aggressive clinical ER+ breast cancers.

INTRODUCTION

Epidemiologic evidence has linked higher levels of circulating prolactin (PRL) with increased risk for estrogen receptor alpha (ER+) breast cancers, particularly in postmenopausal women (Tikk et al., 2014; Tworoger and Hankinson, 2008; Tworoger et al., 2013). However, the role of PRL in tumor progression is more controversial (Hachim et al., 2016; Shemanko, 2016; Tworoger and Hankinson, 2008). Moreover, activation of STAT5A, the downstream mediator of canonical PRL signals, is associated with a better prognosis (Peck et al., 2012; Tworoger and Hankinson, 2008). To distinguish the contributions of PRL to breast cancer from its actions in pregnancy, we generated the NRL-PRL mu-

rine model, where transgenic rat PRL (rPRL) is secreted by mammary epithelia to mimic the local production of PRL reported in women (Marano and Ben-Jonathan, 2014; McHale et al., 2008; O'Leary et al., 2015; Rose-Hellekant et al., 2003). In young adult nulliparous NRL-PRL females, prior to evidence of detectable mammary lesions, ductal epithelia proliferate more rapidly and exhibit increased progenitor activity and Wnt signaling, resulting in reduced maturation of luminal progenitors compared with wild-type (WT) littermates (O'Leary et al., 2017; Rose-Hellekant et al., 2003). With age, NRL-PRL females develop hyperplastic lesions that strongly express ER and progesterone receptor (PR) and eventually develop histologically diverse and metastatic carcinomas (O'Leary et al., 2015; Rose-Hellekant et al., 2003). In contrast to the preneoplastic lesions, established tumors express variable ER and low PR, resembling the luminal B subtype of clinical breast cancer (Arendt et al., 2011; O'Leary et al., 2015).

To understand the mechanisms that underlie the ability of PRL to drive the development of cancers in this model, we used comprehensive genomic analyses to identify genomic alterations and patterns of gene expression associated with cancer progression. In a discovery set of five independent, histologically diverse carcinomas and matched adjacent tumor-free mammary glands from aged NRL-PRL females, we found that all tumors contained somatic alterations in *Kras*, including canonical activating mutations (i.e., G12, G13, and Q61) or amplifications that resulted in elevated *Ras* pathway activation. *Kras* was not altered in any preneoplastic mammary glands. Our findings were validated in an extension set of 22 tumors and 4 cell lines (derived from two additional tumors), demonstrating activating *Ras* alterations in 79% of tumors. *Ras* activation was associated with increased phosphorylation of ERK1/2 and transcripts for *Ras* target genes and some pathway mediators, but variable *rPrI* transgene expression and reduced canonical downstream mediators of PRL signaling. These findings coincide with recent reports that elevated *Ras* signaling drives many clinical luminal B cancers and is associated with a poor prognosis (Olsen et al., 2017; Wright et al., 2015). In contrast to *Kras*-activated tumors, preneoplastic mammary glands maintained constitutive expression of *rPrI* and displayed elevated transcripts for inflammatory cytokines. Together, these data indicate that constitutive PRL signaling in






Figure 1. Sample Cohort Summary

(A) For our discovery set, mammary cell preparations (MCPs) were isolated from caudal glands of 12-week-old NRL-PRL females (MCPs A–E, n = 5). Nulliparous mice with matched end-stage tumors (T) and adjacent aged mammary glands (AMGs) were collected following development of spontaneous ER+ tumors (15–20 months; T1–T5, AMG1–AMG5, n = 5). All samples were examined by RNA-seq. Tumors and matched tail DNA samples underwent WGS and WES.

(B) In our extension set, we evaluated 22 additional tumors from NRL-PRL females (T6–T27) and 4 cell lines (derived from 2 independent tumors).

(C) Summary of samples interrogated in this study. The number of mice associated with each group or the sample identifiers are indicated in parentheses. *Four cell lines were derived from 2 additional independent tumors (2 each).

See Table S1 for further details.

mammary glands induces a pro-tumor environment, facilitating Ras pathway activation and spontaneous tumorigenesis.

RESULTS

To understand the molecular events underlying development of the prolactin-induced carcinomas in NRL-PRL females, we interrogated a discovery set from 10 NRL-PRL nulliparous female mice, consisting of five young adults and five aged tumor-bearing mice. Mammary cell preparations (MCPs) were harvested from the caudal glands of NRL-PRL females (n = 5) at 12 weeks (young adults), prior to morphologic evidence of pathology. Following the formation of spontaneous tumors at 15–20 months of age, three tissues from these mice were collected: (1) end-stage mammary tumors, (2) adjacent non-tumor mammary tissue (aged mammary glands [AMGs]), and (3)

matched tail tissue (Figure 1A; Table S1). Mammary glands from 12-week-old mice contained primarily simple ductal structures and expressed ER and PR at levels similar to WT age-matched females (Figure 2A). In contrast, mammary glands of aged NRL-PRL females contained hyperplastic epithelial structures and expressed ER/PR similar to ductal structures of young glands of either genotype (Figure 2B). The ER+ tumors that develop in this model are histotypically diverse, including more differentiated adenocarcinomas (such as T2 and T3) and less differentiated spindle cell carcinomas (such as T1, T4, and T5). These end-stage tumors expressed lower levels of PR than structures in nondysplastic or hyperplastic AMGs (Figure 2B).

Genomic Characterization

Whole-genome sequencing (WGS) and whole-exome sequencing (WES) were performed on end-stage tumors and matched tails for




Figure 2. Histology of Sequenced Mammary Glands and Histologically Diverse Carcinomas

(A) Mammary glands of 12-week-old NRL-PRL females did not exhibit marked morphological differences and did not express different levels of ER and PR from wild-type (WT) age-matched females.

(B) Histology of tumors sequenced and characterized in the discovery set and representative adjacent glands.

ER, estrogen receptor alpha; PR, progesterone receptor. Scale bars, 50 μ m.

mice within the discovery set ($n = 5$). Somatic variants were detected by comparing tumors with matched tail sequencing data. A range of 3–20 nonsilent mutations (median, 12) were identified in each tumor (Figures 3A and S1; Table S2). *Kras* was the only recurrently mutated gene in this cohort, with missense mutations detected in 4 of 5 tumors. Activating mutations occurred at two known hotspots (three G12D and one Q61L) and were present among the highest fractions (13%–67% DNA variant allele fraction [VAF]) within tumors, suggesting their presence in the founding clone of the tumors. *Kras*-activating mutations were confirmed in the RNA of end-stage tumors (at 46%–75% VAF); however, they were not present in RNA derived from adjacent AMG tissues. The tumor without an activating mutation (T5) was assessed for

copy number and structural variants of *Kras*, and a focal amplification and structural variant were identified containing the *Kras* gene locus. There were no large-scale copy number alterations, structural variants, or gene-gene fusions recurrently altered across the discovery set outside of *Kras* (Figure S1).

Confirmation of *Kras* Activation in *rPrI*-Induced Tumors

We hypothesized that prolonged PRL exposure was creating a selective bottleneck for activating *Kras* mutations in the NRL-PRL mouse model. To determine whether mutations at this locus were consistent in a larger set of these tumors, Sanger sequencing was performed on *Kras* exons 2 and 3 (containing the G12, G13, and Q61 hotspot loci) in an extension set of 22 independent PRL-induced tumors (15 archival tumors [T6–T20] and 7 fresh tumors with matched tails [T21–T27]) and 4 cell lines derived from 2 additional PRL-induced tumors (Figure 1B; Table S1). Hotspot mutations were identified in 14 tumors and all cell lines in this set (Figure 3B; Table 1). Overall, the most common alteration was *Kras* G12D ($n = 9$).

WES was performed on the eight tumors within the extension set that did not contain *Kras*-activating mutations in exons 2 or 3. The mutational burden in these tumors ranged from 0–12 (median 6). Other mutations were not identified in *Kras*; however, there was a missense mutation in *Nras* in one tumor (T21, A59D, 21.3% VAF; Table S2). The copy number landscape was evaluated for *Kras* copy number alterations, as identified in T5 from the discovery set. Copy number was evaluated by quantifying the depth of exome sequencing and normalized per sample. A putative copy number increase in *Kras* was identified in one other tumor (T23), with an average copy number of 7.76 (Figure 3C). For reference, the average copy number within the discovery set was 1.34, whereas T5 exhibited an average copy number of 29. Given that an increased copy number is significantly associated with higher *Kras* expression in T5, we hypothesized that copy number alterations in sample T23 could affect transcript expression (Figure 3D). Together, these data demonstrated that at least 23 of 29 (79%) independent spontaneous NRL-PRL tumors developed alterations in Ras genes. We were unable to identify similar somatic alterations using WES in 6 tumors from the extension set (T6, T7, T12, T13, T17, and T25). Five of these tumors did not have matched normal tails available, reducing confidence in somatic mutation calling and filtering. Additional WGS of these tumors may provide further resolution of the somatic landscape. We focused our subsequent expression analysis on the discovery set, which, like the majority of the tumors, had *Kras*-activating alterations.

Analysis of Human Genomic Datasets for Ras Mutation Recurrence

We queried previously reported clinical datasets to better understand how the NRL-PRL mouse model can be used to comprehend ER+ human breast cancers. Consistent with the spontaneous tumors that arise in this model, amino acid G12 is the most recurrently mutated position in *KRAS* (Figure 3B; Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Curtis et al., 2012; Griffith et al., 2018; Lefebvre et al., 2016; Stephens et al., 2012). This analysis was extended to include other RAS proteins




Figure 3. Summary of *Kras* Modifications in NRL-PRL Tumors

(A) The mutation frequency ranged from 3–20 nonsynonymous coding mutations across the five tumors in the discovery set (median, 12; top bar chart). The mutation burden (mutations per megabase) is shown. The only recurrently mutated gene in our cohort was *Kras* (top row of the bottom plot). The waterfall plot indicates the types of mutations detected in the remainder of the cohort (as detailed in the legend below C).

(B) Schematic of all mutations, comparing the prevalence of *Kras* missense mutations in tumors in NRL-PRL mice (n = 29; 20 contained *Kras* missense mutations) with *KRAS* missense mutations in human breast cancer: The Cancer Genome Atlas [TCGA], n = 825; METABRIC, n = 2,056; Lefebvre et al. (2016), n = 216; Stephens et al. (2012), n = 100; Banerji et al. (2012), n = 103; Griffith et al. (2018), n = 1,038.

(C) Left: Normalized depth of sequencing (coverage normalized by respective sample total sequencing depth) over the exons spanning the *Kras* gene locus (in 320- to 920-bp windows) of all tumor and normal samples. Tumor samples are not normalized with respect to matched normal data because matched normal tails were not available for all mice. Right: the average depth of sequencing (all windows) within the *Kras* locus is indicated on a log₂ scale. Amplifications detected in T5 and T23 are labeled.

(D) RNA-seq data were available for T1–T5 (discovery set). The copy number (right panel, C) of *Kras* is plotted along the x axis, and the gene expression of *Kras* (in fragments per kilobase transcript per million mapped reads [FPKM]; quantified by Cufflinks, see STAR Methods) is indicated on the y axis. Note, two points nearly overlap. Refer to Figures S1 and S2 and Table S3 for further details.

and RasGAP tumor suppressors (*KRAS*, *NRAS*, *HRAS*, *RASAL2*, and *DAB2IP*) because of recent evidence revealing that a high proportion of luminal B ER+ breast cancers display elevated Ras pathway activity as a result of attenuated expression or somatic loss of RasGAP proteins (Olsen et al., 2017; Wright et al., 2015). Thus, although the frequency of *KRAS* alterations is low in human breast cancers (0%–6.94%), the Ras pathway is

altered in 3.8%–22.9% of patients with ER+ breast tumors (Figure S2; Table S3).

Ras Pathway Activation Differentiates Expression in Tumors and Dysplastic Glands

Gene expression was evaluated across the samples from the discovery set, including five nondysplastic MCPs from young

Table 1. Summary of Ras Alterations in the Discovery and Extension Sets

Mutation Type	Sample Source		
	Cell Line	Tumor	Total
WT		6	6
Kras amplification		2	2
Kras G12	2	12	13
G12C		3	3
G12D		9	9
G12V	2		1
Kras G13		1	1
G13A		1	1
Kras Q61	2	5	6
Q61H	2	1	2
Q61L		1	1
Q61R		3	3
Nras A59		1	1
A59D		1	1
Number of mutated samples (tumors)	4 (2) ^a	21	25 (23)
Number of total samples (tumors)	4 (2) ^a	27	31 (29)

^aFour cell lines were derived from 2 additional independent tumors (2 each). In total, 29 independent tumors were evaluated; 23 (79%) had detectable Ras pathway mutations.

females and dysplastic AMGs and end-stage tumors from five aged tumor-bearing mice. Unsupervised approaches indicated clustering based upon sample source, where end-stage tumors behaved more similar to other tumors than their matched adjacent AMGs (Figure 4A). To understand the varied expression patterns across sample types, we first quantified *rPr1* transgene expression in each sample. *rPr1* expression was maintained in both nondysplastic MCPs and dysplastic AMGs but varied in tumors (Figure 4B). Lower-grade, more differentiated tumors (T2 and T3) contained relatively high levels of transgene transcripts, whereas high-grade spindle cell carcinomas (T1, T4, and T5) expressed very low levels of *rPr1* mRNA. This association suggests that *rPr1* transgene expression may influence tumor phenotype but is not required for tumor maintenance.

To determine the downstream effects specific to *Kras* activation, supervised differential expression analysis was performed, comparing matched tumors with adjacent AMGs. There were 41 genes that were differentially expressed between these two tissue types ($q < 0.001$) that were also annotated as part of the Kyoto Encyclopedia of Genes and Genomes (KEGG) Ras pathway (mmu04014). This included upregulation of *Mapk1*, *Map2k1*, and *Src* mRNAs in end-stage tumors (Figure 4C), indicating higher levels of transcripts for mediators of the Ras pathway in *Kras*-driven tumors than in AMGs. Consistently, tumors, but not adjacent AMGs, displayed strong phosphorylation of ERK1/2 and AKT by immunohistochemistry (Figure 4D).

In normal mammary function, most PRL signals are mediated by the JAK2/STAT5A pathway (Oakes et al., 2008). Activation of this signaling cascade results in phosphorylation and dimerization of STAT5A, which then translocates to the nucleus to regulate transcription (Hammarén et al., 2018). Interestingly, *Stat5a*

mRNA was significantly reduced in end-stage tumors compared with AMGs (Wald test, $q = 1.54e-5$; Figure 4C), particularly in poorly differentiated tumors T1, T4, and T5. Non-tumor mammary structures adjacent to the tumors also displayed strong nuclear STAT5A staining (Figure 4D), suggesting that the constitutive *rPr1* expression seen consistently across AMGs was activating this signaling cascade.

Tumorigenic Processes and the Microenvironment Differ across Stages of Disease Progression

Subsequent gene set enrichment and pathway analyses using the RNA sequencing (RNA-seq) data from the discovery set revealed multiple changes with respect to disease progression. Upregulation of tumorigenic processes, including cell cycle regulation and cell adhesion, were associated with Ras pathway activation in end-stage tumors (Tables S4 and S5; Figures 5A and 5B). Chromosome organization and chromatin structure, mitotic nuclear division, as well as cadherin and proteins involved in cell adhesion and adherens junctions were significantly upregulated in tumors compared with AMGs or MCPs (Figure 5B). This is consistent with increased mitotic and invasive properties of cancer cells. AMGs displayed increased expression of genes related to fatty acid metabolism and adipogenesis relative to MCPs and tumors ($p < 0.01$; Figures 5A and 5B), reflecting the higher proportion of adipocytes in these preparations.

Compared with MCPs, both AMGs and tumors showed significantly lower expression of processes related to immune activation, including leukocyte cell-cell adhesion and aggregation, and T cell activation ($q < 0.01$; Tables S4 and S5; Figures 5A and 5B). These observations led us to hypothesize that the immune microenvironment differed across stages of disease. Markers of hematopoietic and immune cell lineages were significantly downregulated in tumors compared with preneoplastic cells, including *Ptprc*, *Cd8a*, *Cd4*, *Tra*, *Trb*, *Cd40*, and *Cd19* mRNAs ($p < 0.001$), suggesting that tumors have reduced immune infiltrate, specifically those responsible for adaptive immune recognition and rejection (Table S4). We therefore interrogated the RNA-seq data to predict the relative proportions of infiltrating immune cell subpopulations using deconvolution approaches to further resolve the immune landscape across the discovery set (Chen et al., 2018). All samples displayed a mixture of immune cell subpopulations, and each tumor showed considerable diversity in the predicted proportions of these immune cell types (Figure 5C). Macrophages represented the predominant immune cell population across all samples (Figure 5C); however, these algorithmic approaches only determined the relative proportion of immune cell subpopulations without quantifying the absolute levels of immune infiltrate in each sample.

To confirm findings and evaluate trends in the RNA-seq data, we examined select transcripts by RT-PCR in the discovery set. In addition, MCPs were generated from WT 12-week-old females (WT MCPs) and from aged NRL-PRL females (aged mammary cell preparations [AMCPs]), enabling us to assess processes associated with preneoplastic changes in similar mammary cell preparations. Lipid metabolic enzymes (*Acadm* and *Fasn* mRNAs) were significantly upregulated in AMGs compared




Figure 4. Constitutive Prolactin Signaling Induces a Selective Bottleneck for Ras Pathway Activation

(A) Unsupervised principal-component analysis was performed across nondysplastic MCPs (n = 5), AMGs (n = 5), and end-stage spontaneous ER+ tumors (n = 5) from the discovery set. The color indicates the sample type.

(B) Kallisto was used to quantify transgene expression in transcripts per million (TPM). Pseudoalignment of RNA reads was performed against the annotated mouse transcriptome and *rPrI* (ENSRNOT00000023412.4).

(C) Heatmap displaying expression of canonical downstream mediators of prolactin signaling (*Jak2* and *Stat5a*) and Ras pathway mediators (*Mapk1/3*, *Akt1/2/3*, *Src*, *Map2k1*, and *Kras*). Fill indicates the expression level in FPKM for AMG and tumor samples from the discovery set.

(D) Immunohistochemical staining for STAT5A, pERK1/2, and pAKT in two representative tumors of different histotypes with adjacent glands (left and right). Tumor regions are indicated by T in the image, and arrows point to adjacent AMGs. Scale bars, 50 μ m.

with AMCPs, confirming that the AMG preparations of tissue adjacent to tumors were enriched with adipocytes (Figure 6A).

To further elucidate the stages of PRL-induced pathogenesis, hormone receptors and signaling pathways were interrogated. Although transcripts for ER α (*Esr1*) were not altered across samples, *Pgr* transcripts fell markedly with disease progression (Figure 6B), confirming detected protein expression (Figure 2).

Acquisition of somatic alterations in *Kras* in tumors was associated with loss of *Stat5a* mRNA (Figure 6C), consistent with the reduction in nuclear STAT5A protein (Figures 4C and 4D). Increased Notch activity, indicated by *Hes1* transcripts, and *Ccne1* mRNA in both AMCPs and tumors were consistent with increased proliferation of preneoplastic epithelial populations and tumors in NRL-PRL females (Zender et al., 2013). However, *Ccnd1*, *Padi4*, and *Hmga2* transcripts were upregulated only in tumors, indicating high proliferation and chromatin remodeling, well-recognized cell-autonomous effects of elevated Ras activity; the dramatic rise in CCND1 protein expression in tumors was confirmed using immunohistochemistry (IHC) (Figures 6D and 6G, i). Unsurprisingly, tumors also showed striking elevations in transcripts associated with invasion and interaction with the extracellular matrix (*Itgb4* and *Mmp9*) (Figure 6E).

Interrogation of cytokines and immune mediators revealed significant differences between tumors and preneoplastic mammary tissue (Figure 6F). Hyperplastic AMCPs, prior to *Kras* alterations, displayed elevated levels of *Nfkb1*, *Csf1*, *Csf2*, *Ifng*, and *Tgfb1* mRNAs, encoding inflammatory cytokines. However, most of these transcripts, along with *Icam1* mRNA, were precipitously lower in established tumors, depicting an immunosuppressed environment. This was reflected in the low numbers of CD8+ intratumoral lymphocytes (Figure 6G, ii), confirming the

RNA-seq data (Tables S4 and S5; Figure 5C). In contrast, intratumoral F4/80+ myeloid cells were plentiful (Figure 6G, iii; as predicted in Figure 5C). *Tgfb1* remained elevated, and *Arg1* and *Nos2* transcripts were increased in tumors, consistent with shifts in activation of resident myeloid populations, including macrophages and myeloid-derived suppressor cells (Sica and Bronte, 2007). Together, these data support marked changes in the immune microenvironment in PRL-induced mammary pathogenesis.

DISCUSSION

Increased local exposure to PRL in the NRL-PRL model results in spontaneous diverse ER+ mammary cancers after a long latency, mimicking clinical luminal B, ER+ cancers in postmenopausal women. Here we demonstrated that Ras pathway activation in this model, particularly through recurrent somatic alterations in *Kras*, follows constitutive PRL signaling. Elevated Ras activity was associated with reduced activity in the canonical PRL-JAK2/STAT5A signaling cascade despite continued transgene expression in some tumors. Transcriptome analyses over the course of oncogenesis revealed marked alterations associated with Ras activity in established tumors in cell-intrinsic processes associated with mitosis, cell adhesion, and invasion as well as in the tumor microenvironment, including immune activity.

Mirroring the connection to human disease (Tikk et al., 2014; Tworoger and Hankinson, 2008; Tworoger et al., 2013), PRL has been observed to promote mammary carcinogenesis in multiple genetically engineered mouse models (Arendt and Schuler, 2008). Elevated PRL accelerates tumor development




Figure 5. Tumorigenic Processes Differ across Stages of Disease Progression

(A) Supervised differential expression analysis was performed on all comparisons of nondysplastic MCPs (n = 5), AMGs, and end-stage tumors (n = 5) from the discovery set. Genes that were significantly upregulated ($p < 0.0001$) in either tumors (compared with AMGs and MCPs) or glands (compared with tumors and MCPs) that were also annotated within significantly upregulated GO annotations ($p < 0.001$) are shown in the heatmap (n = 229). Fill indicates the gene-median centered expression value, calculated with respect to the entire discovery set. GO annotations were grouped into cellular processes, and genes corresponding to each annotation are noted in the side color bar (STAR Methods).

(B) A representative set of differentially expressed GO processes, categorized as “Cell Cycle” and “Immune Processes” in (A), are displayed based on their q value. Following each GO process, the number of genes included in the annotation is indicated. Comparisons are summarized as those that were upregulated in either MCPs or tumors compared with the other sample types.

(C) seq-ImmCC was used to predict the relative proportions of immune cell populations (y axis) in MCPs, AMGs, and end-stage tumors from the discovery set. Samples are ordered by identifier (MCP A–E, AMG 1–5, and Tumors 1–5). Refer to Tables S4 and S5 for further details.

in combination with other oncogenes (Arendt et al., 2006, 2009; O’Leary et al., 2014), and, conversely, its absence increases tumor latency in combination with viral oncogenes (Oakes et al., 2008; Vomachka et al., 2000). Interestingly, BALB/c mice implanted with pituitary isografts, which elevate circulating PRL, develop mutagen-induced mammary tumors that also exhibit mutations in *Kras* (Guzman et al., 1992). Furthermore, expression

of transgenic *Kras* G12V in beta lactoglobulin-expressing mammary cells during lactation (driven in part by high PRL) results in ER+ tumors in C57BL/6 mice (Andò et al., 2017). The link between PRL and development of Ras-driven mammary tumors in these distinct mouse models in different genetic backgrounds points to strong complementarity of these signals in mammary oncogenesis.

RT-PCR Validation




Figure 6. Validation of RNA-Seq Findings

(A–F) RT-PCR was used to evaluate transcripts associated with cellular processes altered with oncogenesis (identified in Figure 5) across samples in the discovery set (MCP, AMG, and tumor; indicated by †) as well as aged mammary cell preparations from NRL-PRL females (AMCP). These include fatty acid metabolism (A), hormone receptors (B), signaling pathways (C), cell cycle (D), cell adhesion (E), and immune processes (F). MCPs were also isolated from wild-type young adults (WT MCP) ($n = 4–5$). Data are represented as mean \pm SEM. Significant differences were determined by one-way ANOVA, followed by the Tukey post-test. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

(G) Immunohistochemistry demonstrating higher levels of CCND1 expression in tumors compared with preneoplastic tissue (i), low levels of CD8+ intratumoral lymphocytes compared with mammary lymphoid tissue (inset, ii), and F4/80+ myeloid cells within tumors and stroma and surrounding preneoplastic structures (inset, iii). Scale bars, 50 μ m.

Germline ablation of *Stat1* in 129/SvEv mice results in mammary tumors that acquire a truncating mutation in *Prlr*, resulting in its constitutive activation (Griffith et al., 2016). The well-differentiated tumors in *Stat1*^{-/-} mice are characterized by strong STAT5 phosphorylation (Chan et al., 2014), similar to tumors that develop in response to transgenic *Stat5a* (Iavnilovitch et al., 2004). However, in NRL-PRL females, the robust STAT5 activation in preneoplastic mammary structures was markedly absent in established tumors, associated with reduced *Stat5a* mRNA and acquisition of Ras mutations, demonstrating a transition from the JAK2/STAT5 axis to the Ras signaling pathway. Consistently, tumors that arise in NRL-PRL females lose dependence on JAK2 signaling with disease progression (Sakamoto et al., 2010), whereas mammary tumors in *Stat1*-deficient mice remain dependent on JAK2 (Chan et al., 2014). Together, these data are congruent with a model whereby JAK2/STAT5A signals promote early tumorigenesis, but their ongoing activity supports well-differentiated, less aggressive luminal cancers that are more likely to respond to anti-estrogen therapies (Peck et al., 2012; Rädler et al., 2017).

Although all tumors in the NRL-PRL discovery set developed alterations in Ras family members, any ongoing role of the JAK2/STAT5 pathway and PRL-initiated signals appeared to differ across individual tumors. In the discovery set, the more differentiated adenocarcinomas (T2 and T3) maintained transgenic *rPrl* expression and showed slightly higher *Stat5a* mRNA than the less differentiated spindle cell carcinomas (T1, T4, and T5). Continued STAT5A signals may promote cell adhesion and other differentiated characteristics in these tumors (Nouhi et al., 2006; Sultan et al., 2005), despite the overall reduction of *Stat5a* transcripts compared with preneoplastic cells. PRL is able to initiate a diverse spectrum of signals apart from JAK2/STAT5, including activation of Src and downstream pathways and crosstalk with the Ras cascade itself (Barcus et al., 2013; Erwin et al., 1995; Martín-Pérez et al., 2015). These observations likely account for the controversy surrounding the role of PRL signals in clinical disease (Hachim et al., 2016; Shemanko, 2016).

Analysis of differentially expressed genes and associated processes with disease progression revealed complex alterations in cell signaling, the cytokine milieu, and the immune microenvironment early in PRL-driven pathogenesis. Together with PRL-augmented mammary epithelial progenitor cell subpopulations (O'Leary et al., 2017), our findings predict elevated inflammatory cytokines prior to acquisition of Ras pathway mutations that may contribute to tumorigenesis. End-stage tumors with genetic alterations in *Kras* exhibited marked modulation of the immune response, including reduced expression of inflammatory cytokines and increased markers of activated myeloid cells. These findings are consistent with the literature describing immune evasion by *Kras* activation by multiple mechanisms, including reduced expression of tumor antigens and promotion of recruitment and differentiation of immune populations that inhibit anti-tumor immune activity (Cullis et al., 2018; Dias Carvalho et al., 2018). Future studies will elucidate interactions between preneoplastic or malignant epithelial cells and the immune microenvironment through stages of PRL-induced pathogenesis.

The low rate of somatic mutations, reduced levels of transcripts encoding markers of many immune cell lineages, and low numbers of CD8+ infiltrating lymphocytes in NRL-PRL tumors mimic the relative immune silence of clinical luminal breast cancers (Dieci et al., 2016; Luen et al., 2016; Vonderheide et al., 2017). Recent studies have revealed that a high proportion of luminal B ER+ breast cancers display elevated Ras pathway activity as a result of reduced expression or somatic loss of Ras-GAP tumor suppressors (Griffith et al., 2018; Olsen et al., 2017; Wright et al., 2015). Thus, although the frequency of *KRAS* alterations is low, collectively, RAS proteins and RasGAP tumor suppressors (*KRAS*, *NRAS*, *HRAS*, *RASAL2*, and *DAB2IP*) are altered in a significant subset of ER+ breast tumors in publicly available datasets (Figure S2; Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Curtis et al., 2012; Griffith et al., 2018; Lefebvre et al., 2016; Stephens et al., 2012). RAS itself has been an elusive therapeutic target (McCormick, 2015; Tran et al., 2016). However, targeting RAS-modulated immune regulators (Candido et al., 2018; Mitchem et al., 2013) may intercept T cell-suppressive signaling by pro-tumor myeloid populations. This approach may facilitate responses to T cell-directed therapies, such as the recent exciting anecdotal report of T cell transfer in metastatic breast cancer (Zacharakis et al., 2018).

For many years, it was questioned whether mouse models of mammary cancer could be estrogen responsive and model clinical luminal breast cancers. However, the ER+ cancers that develop in the NRL-PRL model, like the *Stat1*^{-/-} and *Kras* (G12V) models (Andò et al., 2017; Chan et al., 2012), demonstrate that the tools available for murine systems can be valuable to study ER+ breast cancer. Even in PRL-induced tumors that have lost dependence on estrogen for growth, ER-mediated signals continue to modulate cell phenotype and cancer stem cell activity (Shea et al., 2018). These preclinical immunocompetent models of estrogen-responsive mammary tumors can provide insight into the biological behavior of these cancers, including metastasis, tumor cell plasticity and cancer stem cell activity, therapeutic responsiveness, and patterns of resistance. We would like to emphasize the critical need for comprehensive genomic studies in relevant experimental models to understand the similarities and differences from human disease and optimize the translational efficacy of these models. Without such genomic profiling, many models are being used and interpreted without understanding the full set of molecular alterations that drive and define the model. Our studies of tumorigenesis in the NRL-PRL model describe the ability of constitutive *rPrl* expression to create a pro-tumor mammary environment converging into a selective bottleneck conducive for Ras pathway activation, which initiates aggressive tumor growth, invasion, and immunosuppression of the tumor microenvironment, features shared with a subset of clinical ER+ breast cancers.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY

- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Mice
 - Sample Acquisition
- **METHOD DETAILS**
 - Morphological and Immunohistochemical Analyses
 - Library Construction and Sequencing Strategy
 - Sanger Validation Sequencing
 - DNA sequencing and analysis
 - Publicly Available Datasets
 - rPrI Expression Analysis
 - RNA Expression Analysis
 - RT-PCR
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
 - Statistical Analysis
- **DATA AND CODE AVAILABILITY**

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2019.06.098>.

ACKNOWLEDGMENTS

K.M.C. was supported by the Cancer Biology Pathway through the Siteman Cancer Center at Washington University School of Medicine. M.G. was supported by the National Human Genome Research Institute (R00 HG007940). L.A.S. was supported by the NIH (R01 CA157675 and R01 CA179556) and UWCCC core grant NIH P30 CA014520. O.L.G. was supported by the National Cancer Institute (K22 CA188163 and U01 CA209936).

AUTHOR CONTRIBUTIONS

M.G., L.A.S., K.A.O., and O.L.G. developed the project concept and experimental design. K.M.C. led sequencing experiments and data analysis. K.M.C., E.K.B., Z.L.S., and W.A.M. performed data analysis and prepared figures and tables. K.A.O. and D.E.R. developed methods and carried out mouse experiments and analyses. K.M.C. wrote the manuscript with input from K.K., M.G., K.A.O., L.A.S., and O.L.G.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: October 15, 2018

Revised: April 4, 2019

Accepted: June 27, 2019

Published: July 30, 2019

REFERENCES

Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count data. *Genome Biol.* *11*, R106.

Andò, S., Malivindi, R., Catalano, S., Rizza, P., Barone, I., Panza, S., Rovito, D., Emprou, C., Bornert, J.-M., Laverny, G., and Metzger, D. (2017). Conditional expression of Ki-Ras^{G12V} in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ER α)-positive adenocarcinoma. *Oncogene* *36*, 6420–6431.

Arendt, L.M., and Schuler, L.A. (2008). Transgenic models to study actions of prolactin in mammary neoplasia. *J. Mammary Gland Biol. Neoplasia* *13*, 29–40.

Arendt, L.M., Rose-Hellekant, T.A., Sandgren, E.P., and Schuler, L.A. (2006). Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice. *Am. J. Pathol.* *168*, 1365–1374.

Arendt, L.M., Evans, L.C., Rugowski, D.E., Garcia-Barchino, M.J., Rui, H., and Schuler, L.A. (2009). Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. *J. Endocrinol.* *203*, 99–110.

Arendt, L.M., Rugowski, D.E., Grafwallner-Huseth, T.A., Garcia-Barchino, M.J., Rui, H., and Schuler, L.A. (2011). Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. *Breast Cancer Res.* *13*, R11.

Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K.K., Carter, S.L., Frederick, A.M., Lawrence, M.S., Sivachenko, A.Y., Sougnez, C., Zou, L., et al. (2012). Sequence analysis of mutations and translocations across breast cancer subtypes. *Nature* *486*, 405–409.

Barcus, C.E., Keely, P.J., Eliceiri, K.W., and Schuler, L.A. (2013). Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells. *J. Biol. Chem.* *288*, 12722–12732.

Barnell, E.K., Ronning, P., Campbell, K.M., Krysiak, K., Ainscough, B.J., Ramirez, C., Spiess, N., Kunisaki, J., Hundal, J., Skidmore, Z.L., et al. (2018). Standard operating procedure for somatic variant refinement of tumor sequencing data. *Genet. Med* *21*, 972–981.

Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. *Nature* *490*, 61–70.

Candido, J.B., Morton, J.P., Bailey, P., Campbell, A.D., Karim, S.A., Jamieson, T., Lapienyte, L., Gopinathan, A., Clark, W., McGhee, E.J., et al. (2018). CSF1R⁺ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. *Cell Rep.* *23*, 1448–1460.

Chan, S.R., Vermi, W., Luo, J., Lucini, L., Rickert, C., Fowler, A.M., Lonardi, S., Arthur, C., Young, L.J., Levy, D.E., et al. (2012). STAT1-deficient mice spontaneously develop estrogen receptor α -positive luminal mammary carcinomas. *Breast Cancer Res.* *14*, R16.

Chan, S.R., Rickert, C.G., Vermi, W., Sheehan, K.C.F., Arthur, C., Allen, J.A., White, J.M., Archambault, J., Lonardi, S., McDevitt, T.M., et al. (2014). Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ER α (+) tumorigenesis. *Cell Death Differ.* *21*, 234–246.

Chen, X., Schulz-Trieglaff, O., Shaw, R., Barnes, B., Schlesinger, F., Källberg, M., Cox, A.J., Kruglyak, S., and Saunders, C.T. (2016). Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. *Bioinformatics* *32*, 1220–1222.

Chen, Z., Quan, L., Huang, A., Zhao, Q., Yuan, Y., Yuan, X., Shen, Q., Shang, J., Ben, Y., Qin, F.X.-F., and Wu, A. (2018). seq-ImmuCC: Cell-Centric View of Tissue Transcriptome Measuring Cellular Compositions of Immune Microenvironment From Mouse RNA-Seq Data. *Front. Immunol.* *9*, 1286.

Chiang, C., Layer, R.M., Faust, G.G., Lindberg, M.R., Rose, D.B., Garrison, E.P., Marth, G.T., Quinlan, A.R., and Hall, I.M. (2015). SpeedSeq: ultra-fast personal genome analysis and interpretation. *Nat. Methods* *12*, 966–968.

Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., and Getz, G. (2013). Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat. Biotechnol.* *31*, 213–219.

Cullis, J., Das, S., and Bar-Sagi, D. (2018). Kras and Tumor Immunity: Friend or Foe? *Cold Spring Harb. Perspect. Med.* *8*, a031849.

Curtis, C., Shah, S.P., Chin, S.-F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., et al.; METABRIC Group (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* *486*, 346–352.

Dias Carvalho, P., Guimarães, C.F., Cardoso, A.P., Mendonça, S., Costa, A.M., Oliveira, M.J., and Velho, S. (2018). KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment. *Cancer Res.* *78*, 7–14.

Dieci, M.V., Griguolo, G., Miglietta, F., and Guarneri, V. (2016). The immune system and hormone-receptor positive breast cancer: Is it really a dead end? *Cancer Treat. Rev.* *46*, 9–19.

- Erwin, R.A., Kirken, R.A., Malabarba, M.G., Farrar, W.L., and Rui, H. (1995). Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. *Endocrinology* 136, 3512–3518.
- Faust, G.G., and Hall, I.M. (2014). SAMBLASTER: fast duplicate marking and structural variant read extraction. *Bioinformatics* 30, 2503–2505.
- Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal* 6, p11.
- Griffith, M., Griffith, O.L., Smith, S.M., Ramu, A., Callaway, M.B., Brummett, A.M., Kiwala, M.J., Coffman, A.C., Regier, A.A., Oberkfell, B.J., et al. (2015). Genome Modeling System: A Knowledge Management Platform for Genomics. *PLoS Comput. Biol.* 11, e1004274.
- Griffith, O.L., Chan, S.R., Griffith, M., Krysiak, K., Skidmore, Z.L., Hundal, J., Allen, J.A., Arthur, C.D., Runci, D., Bugatti, M., et al. (2016). Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. *Cell Rep.* 17, 249–260.
- Griffith, O.L., Spies, N.C., Anurag, M., Griffith, M., Luo, J., Tu, D., Yeo, B., Kunisaki, J., Miller, C.A., Krysiak, K., et al. (2018). The prognostic effects of somatic mutations in ER-positive breast cancer. *Nat. Commun.* 9, 3476.
- Guzman, R.C., Osborn, R.C., Swanson, S.M., Sakthivel, R., Hwang, S.I., Miyamoto, S., and Nandi, S. (1992). Incidence of c-Ki-ras activation in N-methyl-N-nitrosourea-induced mammary carcinomas in pituitary-isografted mice. *Cancer Res.* 52, 5732–5737.
- Hachim, I.Y., Shams, A., Lebrun, J.-J., and Ali, S. (2016). A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome. *Hum. Pathol.* 53, 142–152.
- Hammarén, H.M., Virtanen, A.T., Raivola, J., and Silvennoinen, O. (2018). The regulation of JAKs in cytokine signaling and its breakdown in disease. *Cytokine* 118, 48–63.
- Iavnilovitch, E., Cardiff, R.D., Groner, B., and Barash, I. (2004). Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. *Int. J. Cancer* 112, 607–619.
- Keane, T.M., Goodstadt, L., Danecek, P., White, M.A., Wong, K., Yalcin, B., Heger, A., Agam, A., Slater, G., Goodson, M., et al. (2011). Mouse genomic variation and its effect on phenotypes and gene regulation. *Nature* 477, 289–294.
- Koboldt, D.C., Zhang, Q., Larson, D.E., Shen, D., McLellan, M.D., Lin, L., Miller, C.A., Mardis, E.R., Ding, L., and Wilson, R.K. (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res.* 22, 568–576.
- Larson, D.E., Harris, C.C., Chen, K., Koboldt, D.C., Abbott, T.E., Dooling, D.J., Ley, T.J., Mardis, E.R., Wilson, R.K., and Ding, L. (2012). SomaticSniper: identification of somatic point mutations in whole genome sequencing data. *Bioinformatics* 28, 311–317.
- Lefebvre, C., Bachelot, T., Filleron, T., Pedrero, M., Campone, M., Soria, J.-C., Massard, C., Lévy, C., Arnedos, M., Lacroix-Triki, M., et al. (2016). Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. *PLoS Med.* 13, e1002201.
- Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv*, arXiv:1303.3997, <https://arxiv.org/abs/1303.3997>.
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550.
- Luen, S., Virassamy, B., Savas, P., Salgado, R., and Loi, S. (2016). The genomic landscape of breast cancer and its interaction with host immunity. *Breast* 29, 241–250.
- Marano, R.J., and Ben-Jonathan, N. (2014). Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions. *Mol. Endocrinol.* 28, 622–633.
- Martín-Pérez, J., García-Martínez, J.M., Sánchez-Bailón, M.P., Mayoral-Varo, V., and Calcabrini, A. (2015). Role of SRC family kinases in prolactin signaling. *Adv. Exp. Med. Biol.* 846, 163–188.
- McCormick, F. (2015). KRAS as a Therapeutic Target. *Clin. Cancer Res.* 21, 1797–1801.
- McHale, K., Tomaszewski, J.E., Puthiyaveetil, R., Livolsi, V.A., and Clevenger, C.V. (2008). Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. *Mod. Pathol.* 21, 565–571.
- McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernysky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., and DePristo, M.A. (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 20, 1297–1303.
- Mitchem, J.B., Brennan, D.J., Knolhoff, B.L., Belt, B.A., Zhu, Y., Sanford, D.E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013). Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. *Cancer Res.* 73, 1128–1141.
- Nouhi, Z., Chughtai, N., Hartley, S., Cocolakis, E., Lebrun, J.-J., and Ali, S. (2006). Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. *Cancer Res.* 66, 1824–1832.
- O’Leary, K.A., Rugowski, D.E., Sullivan, R., and Schuler, L.A. (2014). Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas. *Oncogene* 33, 3075–3082.
- O’Leary, K.A., Shea, M.P., and Schuler, L.A. (2015). Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse. *Adv. Exp. Med. Biol.* 846, 201–220.
- O’Leary, K.A., Shea, M.P., Saituro, S., Blohm, C.E., and Schuler, L.A. (2017). Prolactin Alters the Mammary Epithelial Hierarchy, Increasing Progenitors and Facilitating Ovarian Steroid Action. *Stem Cell Reports* 9, 1167–1179.
- Oakes, S.R., Rogers, R.L., Naylor, M.J., and Ormandy, C.J. (2008). Prolactin regulation of mammary gland development. *J. Mammary Gland Biol. Neoplasia* 13, 13–28.
- Olsen, S.N., Wronski, A., Castaño, Z., Dake, B., Malone, C., De Raedt, T., Enos, M., DeRose, Y.S., Zhou, W., Guerra, S., et al. (2017). Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. *Cancer Discov.* 7, 202–217.
- Peck, A.R., Witkiewicz, A.K., Liu, C., Klimowicz, A.C., Stringer, G.A., Pequinot, E., Freydn, B., Yang, N., Ertel, A., Tran, T.H., et al. (2012). Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. *Breast Cancer Res.* 14, R130.
- Rädler, P.D., Wehde, B.L., and Wagner, K.-U. (2017). Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells. *Mol. Cell. Endocrinol.* 451, 31–39.
- Rose-Hellekant, T.A., Arendt, L.M., Schroeder, M.D., Gilchrist, K., Sandgren, E.P., and Schuler, L.A. (2003). Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. *Oncogene* 22, 4664–4674.
- Sakamoto, K., Triplett, A.A., Schuler, L.A., and Wagner, K.-U. (2010). Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. *Oncogene* 29, 5359–5369.
- Saunders, C.T., Wong, W.S.W., Swamy, S., Becq, J., Murray, L.J., and Cheetham, R.K. (2012). Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. *Bioinformatics* 28, 1811–1817.
- Sergushichev, A. (2016). An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. *bioRxiv*. <https://doi.org/10.1101/060012>.
- Shea, M.P., O’Leary, K.A., Fakhraideen, S.A., Goffin, V., Friedl, A., Wisinski, K.B., Alexander, C.M., and Schuler, L.A. (2018). Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα⁺ Mammary Carcinomas. *Cancer Res.* 78, 1672–1684.

- Shemanko, C.S. (2016). Prolactin receptor in breast cancer: marker for metastatic risk. *J. Mol. Endocrinol.* *57*, R153–R165.
- Sica, A., and Bronte, V. (2007). Altered macrophage differentiation and immune dysfunction in tumor development. *J. Clin. Invest.* *117*, 1155–1166.
- Skidmore, Z.L., Wagner, A.H., Lesurf, R., Campbell, K.M., Kunisaki, J., Griffith, O.L., and Griffith, M. (2016). GenVisR: Genomic Visualizations in R. *Bioinformatics* *32*, 3012–3014.
- Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge, D.C., Nik-Zainal, S., Martin, S., Varela, I., Bignell, G.R., et al.; Oslo Breast Cancer Consortium (OSBREAC) (2012). The landscape of cancer genes and mutational processes in breast cancer. *Nature* *486*, 400–404.
- Sultan, A.S., Xie, J., LeBaron, M.J., Ealley, E.L., Nevalainen, M.T., and Rui, H. (2005). Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. *Oncogene* *24*, 746–760.
- Tikk, K., Sookthai, D., Johnson, T., Rinaldi, S., Romieu, I., Tjønneland, A., Olsen, A., Overvad, K., Clavel-Chapelon, F., Baglietto, L., et al. (2014). Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. *Ann. Oncol.* *25*, 1422–1428.
- Tran, E., Robbins, P.F., Lu, Y.-C., Prickett, T.D., Gartner, J.J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E.M., et al. (2016). T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. *N. Engl. J. Med.* *375*, 2255–2262.
- Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* *25*, 1105–1111.
- Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., Salzberg, S.L., Wold, B.J., and Pachter, L. (2010). Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat. Biotechnol.* *28*, 511–515.
- Tworoger, S.S., and Hankinson, S.E. (2008). Prolactin and breast cancer etiology: an epidemiologic perspective. *J. Mammary Gland Biol. Neoplasia* *13*, 41–53.
- Tworoger, S.S., Eliassen, A.H., Zhang, X., Qian, J., Sluss, P.M., Rosner, B.A., and Hankinson, S.E. (2013). A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. *Cancer Res.* *73*, 4810–4819.
- Vomachka, A.J., Pratt, S.L., Lockefer, J.A., and Horseman, N.D. (2000). Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. *Oncogene* *19*, 1077–1084.
- Vonderheide, R.H., Domchek, S.M., and Clark, A.S. (2017). Immunotherapy for Breast Cancer: What Are We Missing? *Clin. Cancer Res.* *23*, 2640–2646.
- Wickham, H. (2009). *ggplot2: Elegant Graphics for Data Analysis* (Springer Verlag New York).
- Wright, K.L., Adams, J.R., Liu, J.C., Loch, A.J., Wong, R.G., Jo, C.E.B., Beck, L.A., Santhanam, D.R., Weiss, L., Mei, X., et al. (2015). Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients. *Cancer Res.* *75*, 4960–4972.
- Zacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y.-C., Zheng, Z., Pasetto, A., Langhan, M., Shelton, T., Prickett, T., et al. (2018). Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. *Nat. Med.* *24*, 724–730.
- Zender, S., Nিকেleit, I., Wuestefeld, T., Sørensen, I., Dauch, D., Bozko, P., El-Khatib, M., Geffers, R., Bektas, H., Manns, M.P., et al. (2013). A critical role for notch signaling in the formation of cholangiocellular carcinomas. *Cancer Cell* *23*, 784–795.
- Zerbino, D.R., Achuthan, P., Akanni, W., Amode, M.R., Barrell, D., Bhai, J., Billis, K., Cummins, C., Gall, A., Girón, C.G., et al. (2018). Ensembl 2018. *Nucleic Acids Res.* *46* (D1), D754–D761.
- Zhang, J., White, N.M., Schmidt, H.K., Fulton, R.S., Tomlinson, C., Warren, W.C., Wilson, R.K., and Maher, C.A. (2016). INTEGRATE: gene fusion discovery using whole genome and transcriptome data. *Genome Res.* *26*, 108–118.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Cyclin D1	Biocare Medical	Cat# CP236B
Estrogen receptor	Santa Cruz Biotechnology	Cat# SC-542; RRID:AB_631470
pAKT S473	Cell Signaling Technologies	Cat# 3787; RRID:AB_331170
pERK1/2	Cell Signaling Technologies	Cat# 9101; RRID:AB_331646
STAT5A	Santa Cruz Biotechnology	Cat# SC-1081; RRID:AB_632448
CD8	ThermoFisher	Cat# 14008185; RRID:AB_467088
F4/80	Biologend	Cat# 123102; AB_893506
Progesterone Receptor	Dako	Cat# A0098; RRID:AB_2315192
Biological Samples		
Mammary cell preparations from NRL-PRL mammary glands	This Paper	N/A
Critical Commercial Assays		
Blood & Cell Culture DNA Mini Kit	QIAGEN	13323
TruSeq PCR free WGS library preparation kit	Illumina	20015962
RNEasy Midi Kit	QIAGEN	75142
TruSeq Stranded Total RNA library preparation kit	Illumina	20020596
Phusion Hot Start Flex DNA polymerase	New England Biolabs	M0535
QIAquick PCR Purification Kit	QIAGEN	28104
M-MLV reverse transcriptase	Promega	M1705
SYBR Green	ThermoFisher	4309155
Deposited Data		
Mouse reference genome (NCBI build 38, GRCm38)	Genome Reference Consortium	https://www.ncbi.nlm.nih.gov/assembly/GCF_000001635.26
Ensembl reference transcriptome v84	Ensembl	ftp://ftp.ensembl.org/pub/release-84/gtf/mus_musculus/
Mouse Genomes Project v142	Keane et al., 2011	ftp://ftp-mouse.sanger.ac.uk/REL-1505-SNPs_Indels/
Human breast cancer sequencing dataset	Banerji et al., 2012	http://www.cbioportal.org/
Human breast cancer sequencing dataset	Cancer Genome Atlas Network, 2012	http://www.cbioportal.org/
Human breast cancer sequencing dataset	Curtis et al., 2012	http://www.cbioportal.org/
Human breast cancer sequencing dataset	Lefebvre et al., 2016	http://www.cbioportal.org/
Human breast cancer sequencing dataset	Stephens et al., 2012	http://www.cbioportal.org/
Human breast cancer sequencing dataset	Griffith et al., 2018	phs001234.v1.p1
Raw and analyzed data	This Paper	SRP189110
Experimental Models: Organisms/Strains		
Mouse: NRL-PRL [lines 1647-13, TgN(Nrl-Pr1)23EPS; 1655-8, TgN(Nrl-Pr1)24EPS]	Rose-Hellekant et al., 2003	N/A
Oligonucleotides		
Primers for Real Time PCR, see Table S6	This Paper	N/A
Primers for Sanger Sequencing, see Table S6	This Paper	N/A
Software and Algorithms		
Codon Code Aligner [v 7.0.1]	CodonCode Corporation	https://www.codoncode.com/aligner/
Genome Modeling System	Griffith et al., 2015	https://github.com/genome/gms
BWA-MEM v0.7.10	Li, 2013	https://github.com/lh3/bwa
SAMBLASTER v0.1.22	Faust and Hall, 2014	https://github.com/GregoryFaust/samblaster

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
SomaticSniper v1.0.4	Larson et al., 2012	http://gmt.genome.wustl.edu/packages/somatic-sniper/
VarScan2 v2.3.6	Koboldt et al., 2012	http://varscan.sourceforge.net/
Strelka v1.0.11	Saunders et al., 2012	https://github.com/Illumina/strelka
Mutect v1.1.4	Cibulskis et al., 2013	https://software.broadinstitute.org/cancer/cga/mutect
GATK Somatic Indel Detector v5336	McKenna et al., 2010	https://software.broadinstitute.org/gatk/
Samtools r982	Li et al., 2009	http://samtools.sourceforge.net/
CopyCat v0.1	N/A	https://github.com/chrisamiller/copyCat
Manta	Chen et al., 2016	https://github.com/Illumina/manta
Integrate	Zhang et al., 2016	https://sourceforge.net/projects/integrate-fusion/
cBioPortal	Gao et al., 2013	http://www.cbioportal.org
Kallisto	Zerbino et al., 2018	https://pachterlab.github.io/kallisto/
TopHat	Trapnell et al., 2009	https://github.com/infphilo/tophat
Cufflinks	Trapnell et al., 2010	https://github.com/cole-trapnell-lab/cufflinks
HTSeq-count	Anders and Huber, 2010	https://htseq.readthedocs.io/en/release_0.11.1/
DESeq2	Love et al., 2014	https://bioconductor.org/packages/release/bioc/html/DESeq2.html
Gene set enrichment analysis (fgsea)	Sergushichev, 2016	https://bioconductor.org/packages/release/bioc/html/fgsea.html
Ggplot2	Wickham, 2009	https://ggplot2.tidyverse.org/
GenVisR	Skidmore et al., 2016	https://bioconductor.org/packages/release/bioc/html/GenVisR.html
Seq-ImmuCC	Chen et al., 2018	http://218.4.234.74:3200/immune/
Other		
Manual review standard operating procedures	Barnell et al., 2018	N/A

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Obi Griffith (obigriffith@wustl.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice

NRL-PRL mice [lines 1647-13, TgN(Nrl-Pr)23EPS; 1655-8, TgN(Nrl-Pr)24EPS] were generated and maintained in the FVB/N strain background (O'Leary et al., 2015; Rose-Hellekant et al., 2003). All tumors in the Discovery Set were TgN(Nrl-Pr)23EPS; the Extension Set included archived tumors of both lines. Mice were housed and handled in accordance with the Guide for Care and Use of Laboratory Animals in AAALAC-accredited facilities, and all procedures were approved by the University of Wisconsin-Madison Animal Care and Use Committee.

Sample Acquisition

We examined changes with age and pathogenesis in heterozygotic nulliparous females. Mammary epithelial cells were isolated from 12 week old animals, prior to evidence of morphological abnormalities. Other animals were aged until the primary mammary tumors were 1.5 cm in diameter (end stage), when the tumors, adjacent mammary glands, and tails were collected and flash frozen for subsequent analyses. For the Extension Set, an additional 22 tumors and 2 pairs of cell lines derived from 2 independent tumors were examined. These additional tumors included 7 freshly isolated tumors and matched tails, and 15 archived tumors were equally distributed among the glandular, papillary, and spindle cell carcinoma histotypes. All tumors analyzed developed in the cranial glands, reflecting the predominance of this site in this and many other transgenic mammary cancer models.

METHOD DETAILS

Morphological and Immunohistochemical Analyses

Samples were collected and fixed overnight in 10% neutral buffered formalin and processed into 5 micron sections. Mammary structures were assessed in hematoxylin and eosin (H&E) stained tissue sections, and protein expression was visualized by immunohistochemistry as previously described (Arendt et al., 2011) using antibodies against the following antigens: Cyclin D1, CP236B, Biocare Medical, (1:200); ER, #SC-542, Santa Cruz Biotechnology (1:500); PR, A0098, Dako (1:500); pAKT^{S473}, #3787, Cell Signaling Technologies (1:50); pERK1/2, #9101, Cell Signaling Technologies (1:400); STAT5A, #SC-1081, Santa Cruz Biotechnology (1:5000). For CD8 and F4/80, frozen sections were stained. Tissues were embedded in OCT and frozen in a dry ice/methanol bath. Seven micron sections were cut, fixed with acetone at -20°C for 20 min, blocked with 5% normal goat serum and incubated overnight with either anti-CD8, Clone 53-6.7, Invitrogen (1:1000) or anti-F4/80, Clone BM8, Biolegend, (1:250). Slides were then processed in the same manner as for the paraffin sections.

Library Construction and Sequencing Strategy

Genomic DNA was isolated using the QIAGEN Blood & Cell Culture DNA Mini Kit (#13323; Hilden, Germany). Whole genome sequencing (WGS) libraries for matched tumor and normal tail samples ($n = 5$) were prepared using the Illumina TruSeq PCR free kit with dual indexed adaptors. WGS libraries were pooled and sequenced across 1 flow cell (8 lanes) on the Illumina HiSeq X platform with paired 2×150 bp reads with median 33.35X coverage (27.18-37.52X). Whole exome sequencing (WES) libraries for matched tumor and normal tail samples were pooled and sequenced on 1 lane of an Illumina HiSeq 4000 with paired 2×150 bp reads with median 37.99X coverage (10.39-85.45X). Total RNA was isolated using the QIAGEN RNeasy Midi Kit (#75142; Hilden, Germany). RNA sequencing (RNAseq) libraries were prepared using the Illumina TruSeq stranded total RNA kit. Libraries were pooled and sequenced across 4 lanes of a HiSeq 4000 with 2×150 bp reads with median 60,072,344 total reads (43,482,392-100,068,565 total reads).

Sanger Validation Sequencing

For the Extension Set and positive controls from the Discovery Set, the regions surrounding *Kras* hotspots G12/G13 and Q61 were amplified from 5ng of genomic DNA, using Phusion Hot Start Flex DNA polymerase (#M0535; New England Biolabs), and primers which tagged products with M13F(-21) (forward strand) and M13R (reverse strand) sequences (see Table S6 for Primer Sequences). PCR products were purified using the QIAquick PCR Purification Kit (#28104; QIAGEN), and sent to GeneWiz (South Plainfield, NJ) for Sanger Sequencing. Traces were manually assessed for variants within G12, G13, and Q61 using the CodonCode Aligner software (version 7.0.1; CodonCode Corporation).

DNA sequencing and analysis

The Genome Modeling System (GMS) was used for all analysis, including the somatic variant detection and RNA-seq analysis (Griffith et al., 2015). WGS and WES data were processed through SpeedSeq v0.1.0 (Chiang et al., 2015; Faust and Hall, 2014), which aligns reads by BWA-MEM v0.7.10 (Li, 2013) to the mouse reference genome (NCBI build 38, GRCm38) and marks duplicates using SAMBLASTER v0.1.22 (Faust and Hall, 2014). Matched (normal) tail samples were analyzed for all 5 tumors in the Discovery Set and 3 tumors in the Extension Set which did not exhibit *Kras* G12, G13, or Q61 mutations. Somatic events were identified by individually comparing tumor DNA to matched tail (normal) DNA. Single nucleotide variants (SNVs) were detected by the union of SomaticSniper v1.0.4 (Larson et al., 2012), VarScan2 v2.3.6 (Koboldt et al., 2012), Strelka v1.0.11 (Saunders et al., 2012), and Mutect v1.1.4 (Cibulskis et al., 2013). Small insertions and deletions (indels) were detected by taking the union of GATK Somatic Indel Detector (v5336) (McKenna et al., 2010), Varscan2, and Strelka. 5 tumors from the Extension Set which did not exhibit *Kras* G12, G13, or Q61 mutations did not have DNA from matched normal tail samples (T6, 7, 12, 13, and 17). For these tumors, SNV/indels were detected by comparing the aligned tumor WES data to the mouse reference genome GRCm38 using Varscan 2 (v2.3.6) (Koboldt et al., 2012).

SNV/indels were filtered using Samtools r982 (Li et al., 2009) ([mpileup -BuDS] filtered by var-filter-snv v1 then false-positive-vcf v1) and annotated by the GMS transcript variant annotator against Ensembl v84. Mutations were filtered to those annotated as nonsynonymous Tier 1 mutations within the protein-coding regions, meeting the following thresholds: minimum 5 reads supporting the variant, minimum 5% variant allele frequency, minimum 20X coverage of the corresponding genomic position in the tumor sample, and minimum 20X coverage of the corresponding genomic position in the normal tail sample (if available). The 8 tail samples were used as a 'panel of normal' samples in order to remove common nucleotide polymorphisms and artifacts with the following requirements: SNVs with a minimum 2.5% VAF with 20X coverage detected in at least 2 (25%) of the normal samples or Indels with minimum 2% VAF with 2X coverage detected in at least 2 (25%) of the normal samples. Following this filtering strategy, false positives were manually removed, as previously described (Barnell et al., 2018).

All variants were further filtered by removing those identified in normal mice by the Mouse Genomes Project (v142) (Keane et al., 2011). There were no remaining variants detected in T23, likely indicating that this tumor had low tumor cellularity, making it difficult to differentiate sequencing artifacts from variants detected. There were five tumors (T6, T7, T12, T13, T17) without matched normal tail samples. Recurrent mutations that were identified only in these unmatched tumors were removed as likely germline variants. Furthermore, mutations in olfactory receptor and uncharacterized cDNA regions (*Olf*r and *Rik* genes) were removed.

Copy number variants, including *Kras* amplifications, were identified using CopyCat v0.1 [<https://github.com/chrisamiller/copyCat>], comparing matched tumor and normal tail samples, if available. In tumors with no matched normal samples, copy number alterations were detected by normalizing the depth of sequencing within each sample over the exons spanning the *Kras* gene locus (in 320–920 bp windows). While there were no variants detected in T23, there was increased normalized coverage over the *Kras* gene locus indicating a possible copy number amplification. Structural variants were predicted using Manta on WGS and WES data (Chen et al., 2016), and intergenic fusions were detected using Integrate (Zhang et al., 2016).

Publicly Available Datasets

Clinical and mutational data from five public datasets (Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Curtis et al., 2012; Lefebvre et al., 2016; Stephens et al., 2012) were obtained through cBioPortal (Gao et al., 2013). Samples were filtered to those annotated as ‘Breast Cancer’ (removing ‘Breast Sarcoma’). Patients were annotated as ‘ER+ or HR+/HER2-’ in Figure S2 based upon the ‘ER Status’ and ‘HR+/HER2-’ columns in the clinical annotations. These datasets were specifically queried for mutations and copy number alterations in *KRAS*, *NRAS*, *HRAS*, *DAB2IP*, and *RASAL2*. The Griffith dataset (Griffith et al., 2018) contained only HR+/HER2- breast cancers, and was only assessed for *KRAS* mutations (the other four genes were not evaluated in this targeted gene panel study).

rPrI Expression Analysis

A kallisto index was built to incorporate the annotated Ensembl mouse transcriptome (v92) and the full *rPrI* transcript (ENSRNOT00000023412.4) (Zerbino et al., 2018). RNaseq reads were pseudoaligned to this kallisto index to quantify read abundance and expression (TPM) of *rPrI*.

RNA Expression Analysis

RNaseq reads were aligned to the mouse reference genome (NCBI build 38, GRCm38) using TopHat (Trapnell et al., 2009). Cufflinks (Trapnell et al., 2010) and HTSeq-count (Anders and Huber, 2010) were used to quantify gene and transcript expression, and differential expression analysis was performed using the DESeq2 R package (Love et al., 2014). Gene Set Enrichment Analysis was performed using the fgsea R package (Sergushichev, 2016). The GAGE R package was used for pathway analysis, and data visualization was performed using the ggplot2 R package (Wickham, 2009) and GenVisR (Skidmore et al., 2016). Immune infiltrate was assessed by seq-ImmuCC using the Illumina RNaseq platform and the SVR method (Chen et al., 2018). Immune populations were summarized as relative frequencies (the default output of the program).

RT-PCR

Total RNA was isolated from samples in the Discovery Set (MCPs, AMGs, tumors), WT age-matched (12–14 week) MCPs, and non-tumor mammary cells from aged (15–16 month) mice isolated using the MCP procedure, using the RNeasy Midi Kit (#75142; QIAGEN). cDNA was synthesized from 1 μ g of RNA using M-MLV reverse transcriptase (#M1705; Promega) and random hexamers. Real time PCR was performed using SYBR Green (#4309155; ThermoFisher) on the Applied Biosystems 7300 platform as described (Arendt et al., 2011) using the primer sequences in Table S6. Transcripts of interest were normalized to 18S RNA, and fold changes calculated using the $\Delta\Delta$ Ct method.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical Analysis

Gene expression differences and statistics were summarized by the results of supervised comparisons in DESeq2. Specifically, p values were calculated by Negative Binomial generalized linear model fitting and Wald statistics, and adjusted p values (q values) were calculated by the Benjamini Hochberg method. Immune populations were compared using Mann-Whitney tests between groups.

DATA AND CODE AVAILABILITY

The reference-aligned whole genome, exome, and RNA sequencing data and sample details for 36 tumor and non-tumor mouse tissues have been submitted to NCBI SRA study SRP189110, BioProject PRJNA489661.

Cell Reports, Volume 28

Supplemental Information


A Spontaneous Aggressive ER α + Mammary

Tumor Model Is Driven by Kras Activation

Katie M. Campbell, Kathleen A. O'Leary, Debra E. Rugowski, William A. Mulligan, Erica K. Barnell, Zachary L. Skidmore, Kilannin Krysiak, Malachi Griffith, Linda A. Schuler, and Obi L. Griffith

Figure S2. Ras pathway alterations in human breast cancer datasets. Related to Figure 3 and Table S3.

A. Summary of samples assessed from publicly available human breast cancer datasets. Samples are differentiated as either 'ER+ or HR+/HER2-' or 'ER- or Not Defined' (indicated by color), as described in cBioPortal (Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Curtis et al., 2012; Griffith et al., 2018; Lefebvre et al., 2016; Stephens et al., 2012). **B.** Somatic alterations detected in samples from A, categorized by gene (color) and ER status. Alterations are summarized as copy number amplifications (AMP), homozygous deletion (HOMDEL), or point mutations (MUT). **C-F.** Schematics Lolloplots depicting specific point mutations identified in samples from A across Ras pathway genes (*HRAS*, *NRAS*, *DAB2IP*, and *RASAL2*).



Supplemental Tables

Table S3. Ras pathway alterations in human breast cancer datasets. Related to Figures 3 and S2.

The number of somatic alterations - including mutations, amplifications, and deletions - detected across public datasets. Values indicate the number of patients with alterations in each corresponding gene (row), or the total number of patients with mutations in any gene (bottom row; percent is calculated as the number of patients with alterations within the associated subtype). "NA" indicates that the gene was not evaluated in the corresponding gene (The Griffith et al. dataset did not evaluate mutations in genes other than *KRAS*). * Patients may have alterations in more than one gene.

	METABRIC (n=2,506)		Griffith et al. (n=1,038)	TCGA (n=825)		Lefebvre et al. (n=216)		Banerji et al. (n=103)		Stephens et al. (n=100)	
	ER+ (n=1,824)	ER- (n=682)	ER+ (n=1,038)	ER+ (n=601)	ER- (n=224)	ER+ (n=143)	ER- (n=73)	ER+ (n=44)	ER- (n=59)	ER+ (n=79)	ER- (n=21)
<i>KRAS</i>	22	44	1	7	9	8	7	0	0	1	0
<i>HRAS</i>	16	6	NA	3	2	7	4	0	0	1	0
<i>NRAS</i>	15	4	NA	2	4	1	0	0	0	0	0
<i>DAB2IP</i>	9	9	NA	7	3	1	2	1	0	1	0
<i>RASAL2</i>	374	68	NA	19	6	12	3	1	1	0	0
Total Patients with Alterations* (% of subtype)	417 (22.9%)	121 (17.7%)	1 (0.1%)	37 (6.2%)	24 (10.7%)	26 (18.2%)	14 (19.2%)	2 (4.5%)	1 (1.7%)	3 (3.8%)	0 (0%)